Header Logo

Connection

Theo Manschreck to Adult

This is a "connection" page, showing publications Theo Manschreck has written about Adult.
Connection Strength

0.632
  1. Shahzade C, Chun J, DeLisi LE, Manschreck TC. Patterns in adolescent cannabis use predict the onset and symptom structure of schizophrenia-spectrum disorder. Schizophr Res. 2018 07; 197:539-543.
    View in: PubMed
    Score: 0.060
  2. Manschreck TC, Chun J, Merrill AM, Maher BA, Boshes RA, Glatt SJ, Faraone SV, Tsuang MT, Seidman LJ. Impaired motor performance in adolescents at familial high-risk for schizophrenia. Schizophr Res. 2015 Oct; 168(1-2):44-9.
    View in: PubMed
    Score: 0.049
  3. Manschreck TC, Merrill AM, Jabbar G, Chun J, Delisi LE. Frequency of normative word associations in the speech of individuals at familial high-risk for schizophrenia. Schizophr Res. 2012 Sep; 140(1-3):99-103.
    View in: PubMed
    Score: 0.040
  4. Lenzenweger MF, Miller AB, Maher BA, Manschreck TC. Schizotypy and individual differences in the frequency of normal associations in verbal utterances. Schizophr Res. 2007 Sep; 95(1-3):96-102.
    View in: PubMed
    Score: 0.028
  5. Manschreck TC, Khan NL. Recent advances in the treatment of delusional disorder. Can J Psychiatry. 2006 Feb; 51(2):114-9.
    View in: PubMed
    Score: 0.026
  6. Manschreck TC, Maher BA, Candela SF. Earlier age of first diagnosis in schizophrenia is related to impaired motor control. Schizophr Bull. 2004; 30(2):351-60.
    View in: PubMed
    Score: 0.022
  7. Manschreck TC, Maher BA, Candela SF, Redmond D, Yurgelun-Todd D, Tsuang M. Impaired verbal memory is associated with impaired motor performance in schizophrenia: relationship to brain structure. Schizophr Res. 2000 May 25; 43(1):21-32.
    View in: PubMed
    Score: 0.017
  8. Manschreck TC, Maher BA, Winzig L, Candela SF, Beaudette S, Boshes R. Age disorientation in schizophrenia: an indicator of progressive and severe psychopathology, not institutional isolation. J Neuropsychiatry Clin Neurosci. 2000; 12(3):350-8.
    View in: PubMed
    Score: 0.017
  9. Manschreck TC, Redmond DA, Candela SF, Maher BA. Effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia. J Neuropsychiatry Clin Neurosci. 1999; 11(4):481-9.
    View in: PubMed
    Score: 0.016
  10. White MS, Maher BA, Manschreck TC. Hemispheric specialization in schizophrenics with perceptual aberration. Schizophr Res. 1998 Aug 17; 32(3):161-70.
    View in: PubMed
    Score: 0.015
  11. Manschreck TC, Maher BA, Beaudette SM, Redmond DA. Context memory in schizoaffective and schizophrenic disorders. Schizophr Res. 1997 Aug 29; 26(2-3):153-61.
    View in: PubMed
    Score: 0.014
  12. Pillai A, Schooler NR, Peter D, Looney SW, Goff DC, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz A, Miller DD, Severe JB, Wilson DR, Ames D, Bustillo J, Kane JM, Buckley PF. Predicting relapse in schizophrenia: Is BDNF a plausible biological marker? Schizophr Res. 2018 03; 193:263-268.
    View in: PubMed
    Score: 0.014
  13. Buckley PF, Schooler NR, Goff DC, Kopelowicz A, Lauriello J, Manschreck TC, Mendelowitz A, Miller DD, Wilson DR, Ames D, Bustillo JR, Kane JM, Looney SW. Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study. Psychiatr Serv. 2016 12 01; 67(12):1370-1372.
    View in: PubMed
    Score: 0.013
  14. Manschreck TC. Delusional disorder: the recognition and management of paranoia. J Clin Psychiatry. 1996; 57 Suppl 3:32-8; discussion 49.
    View in: PubMed
    Score: 0.013
  15. Manschreck TC, Redmond DA, Beaudette SM. Clozapine in the back wards. Ann Clin Psychiatry. 1994 Dec; 6(4):215-25.
    View in: PubMed
    Score: 0.012
  16. Buckley PF, Schooler NR, Goff DC, Hsiao J, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz AJ, Miller del D, Severe JB, Wilson DR, Ames D, Bustillo J, Mintz J, Kane JM. Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. Schizophr Bull. 2015 Mar; 41(2):449-59.
    View in: PubMed
    Score: 0.011
  17. Chun J, Karam ZN, Marzinzik F, Kamali M, O'Donnell L, Tso IF, Manschreck TC, McInnis M, Deldin PJ. Can P300 distinguish among schizophrenia, schizoaffective and bipolar I disorders? An ERP study of response inhibition. Schizophr Res. 2013 Dec; 151(1-3):175-84.
    View in: PubMed
    Score: 0.011
  18. Thermenos HW, Whitfield-Gabrieli S, Seidman LJ, Kuperberg G, Juelich RJ, Divatia S, Riley C, Jabbar GA, Shenton ME, Kubicki M, Manschreck T, Keshavan MS, DeLisi LE. Altered language network activity in young people at familial high-risk for schizophrenia. Schizophr Res. 2013 Dec; 151(1-3):229-37.
    View in: PubMed
    Score: 0.011
  19. Goff DC, McEvoy JP, Citrome L, Mech AW, Bustillo JR, Gil R, Buckley P, Manschreck TC, Achtyes ED, Macklin EA. High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study. J Clin Psychopharmacol. 2013 Aug; 33(4):485-90.
    View in: PubMed
    Score: 0.011
  20. Scala S, Pousada A, Stone WS, Thermenos HW, Manschreck TC, Tsuang MT, Faraone SV, Seidman LJ. Verbal and visual-spatial memory impairment in youth at familial risk for schizophrenia or affective psychosis: a pilot study. Schizophr Res. 2013 Mar; 144(1-3):122-8.
    View in: PubMed
    Score: 0.010
  21. Galvez-Buccollini JA, Proal AC, Tomaselli V, Trachtenberg M, Coconcea C, Chun J, Manschreck T, Fleming J, Delisi LE. Association between age at onset of psychosis and age at onset of cannabis use in non-affective psychosis. Schizophr Res. 2012 Aug; 139(1-3):157-60.
    View in: PubMed
    Score: 0.010
  22. Stroup TS, Appelbaum PS, Gu H, Hays S, Swartz MS, Keefe RS, Kim SY, Manschreck TC, Boshes RA, McEvoy JP, Lieberman JA. Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study. Schizophr Res. 2011 Aug; 130(1-3):47-52.
    View in: PubMed
    Score: 0.009
  23. Manschreck TC, Maher B, Celada MT, Schneyer M, Fernandez R. Object chaining and thought disorder in schizophrenic speech. Psychol Med. 1991 May; 21(2):443-6.
    View in: PubMed
    Score: 0.009
  24. Manschreck TC, Schneyer ML, Weisstein CC, Laughery J, Rosenthal J, Celada T, Berner J. Freebase cocaine and memory. Compr Psychiatry. 1990 Jul-Aug; 31(4):369-75.
    View in: PubMed
    Score: 0.009
  25. Manschreck TC, Keuthen NJ, Schneyer ML, Celada MT, Laughery J, Collins P. Abnormal involuntary movements and chronic schizophrenic disorders. Biol Psychiatry. 1990 Jan 15; 27(2):150-8.
    View in: PubMed
    Score: 0.008
  26. Chan RC, Wang Y, Wang L, Chen EY, Manschreck TC, Li ZJ, Yu X, Gong QY. Neurological soft signs and their relationships to neurocognitive functions: a re-visit with the structural equation modeling design. PLoS One. 2009 Dec 24; 4(12):e8469.
    View in: PubMed
    Score: 0.008
  27. Garber HJ, Weilburg JB, Duffy FH, Manschreck TC. Clinical use of topographic brain electrical activity mapping in psychiatry. J Clin Psychiatry. 1989 Jun; 50(6):205-11.
    View in: PubMed
    Score: 0.008
  28. Manschreck TC, Laughery JA, Weisstein CC, Allen D, Humblestone B, Neville M, Podlewski H, Mitra N. Characteristics of freebase cocaine psychosis. Yale J Biol Med. 1988 Mar-Apr; 61(2):115-22.
    View in: PubMed
    Score: 0.007
  29. Manoach DS, Maher BA, Manschreck TC. Left-handedness and though disorder in the schizophrenias. J Abnorm Psychol. 1988 Feb; 97(1):97-9.
    View in: PubMed
    Score: 0.007
  30. Manschreck TC, Maher BA, Milavetz JJ, Ames D, Weisstein CC, Schneyer ML. Semantic priming in thought disordered schizophrenic patients. Schizophr Res. 1988 Jan-Feb; 1(1):61-6.
    View in: PubMed
    Score: 0.007
  31. Manschreck TC, Allen DF, Neville M. Freebase psychosis: cases from a Bahamian epidemic of cocaine abuse. Compr Psychiatry. 1987 Nov-Dec; 28(6):555-64.
    View in: PubMed
    Score: 0.007
  32. Goff DC, Lamberti JS, Leon AC, Green MF, Miller AL, Patel J, Manschreck T, Freudenreich O, Johnson SA. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology. 2008 Feb; 33(3):465-72.
    View in: PubMed
    Score: 0.007
  33. Keefe RS, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, Meltzer HY, Green MF, Miller DD, Canive JM, Adler LW, Manschreck TC, Swartz M, Rosenheck R, Perkins DO, Walker TM, Stroup TS, McEvoy JP, Lieberman JA. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology. 2006 Sep; 31(9):2033-46.
    View in: PubMed
    Score: 0.006
  34. Maher BA, Manschreck TC, Linnet J, Candela S. Quantitative assessment of the frequency of normal associations in the utterances of schizophrenia patients and healthy controls. Schizophr Res. 2005 Oct 15; 78(2-3):219-24.
    View in: PubMed
    Score: 0.006
  35. Stroup S, Appelbaum P, Swartz M, Patel M, Davis S, Jeste D, Kim S, Keefe R, Manschreck T, McEvoy J, Lieberman J. Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophr Res. 2005 Dec 01; 80(1):1-8.
    View in: PubMed
    Score: 0.006
  36. Manschreck TC, Maher BA, Waller NG, Ames D, Latham CA. Deficient motor synchrony in schizophrenic disorders: clinical correlates. Biol Psychiatry. 1985 Sep; 20(9):990-1002.
    View in: PubMed
    Score: 0.006
  37. Manschreck TC, Maher BA, Hoover TM, Ames D. Repetition in schizophrenic speech. Lang Speech. 1985 Jul-Sep; 28 ( Pt 3):255-68.
    View in: PubMed
    Score: 0.006
  38. Manschreck TC, Ames D. Neurologic features and psychopathology in schizophrenic disorders. Biol Psychiatry. 1984 May; 19(5):703-19.
    View in: PubMed
    Score: 0.006
  39. Manschreck TC, Maher BA, Hoover TM, Ames D. The type--token ratio in schizophrenic disorders: clinical and research value. Psychol Med. 1984 Feb; 14(1):151-7.
    View in: PubMed
    Score: 0.006
  40. Manschreck TC. Psychopathology of motor behavior in schizophrenia. Prog Exp Pers Res. 1983; 12:53-99.
    View in: PubMed
    Score: 0.005
  41. Manschreck TC, Maher BA, Rucklos ME, Vereen DR. Disturbed voluntary motor activity in schizophrenic disorder. Psychol Med. 1982 Feb; 12(1):73-84.
    View in: PubMed
    Score: 0.005
  42. Boshes RA, Manschreck TC, Desrosiers J, Candela S, Hanrahan-Boshes M. Initiation of clozapine therapy in a patient with preexisting leukopenia: a discussion of the rationale of current treatment options. Ann Clin Psychiatry. 2001 Dec; 13(4):233-7.
    View in: PubMed
    Score: 0.005
  43. Manschreck TC, Maher BA, Rucklos ME, Vereen DR, Ader DN. Deficient motor synchrony in schizophrenia. J Abnorm Psychol. 1981 Aug; 90(4):321-8.
    View in: PubMed
    Score: 0.005
  44. Manschreck TC, Maher BA, Ader DN. Formal thought disorder, the type-token ratio and disturbed voluntary motor movement in schizophrenia. Br J Psychiatry. 1981 Jul; 139:7-15.
    View in: PubMed
    Score: 0.005
  45. Manschreck TC, Kalotkin M, Jacobson AM. Utility of electromyographic biological feedback in chronic stuttering: a clinical study with follow-up. Percept Mot Skills. 1980 Oct; 51(2):535-40.
    View in: PubMed
    Score: 0.004
  46. Manschreck TC, Maher BA, Rucklos ME. Cloze procedure and written language in schizophrenia. Lang Speech. 1980; 23(Pt 4):323-8.
    View in: PubMed
    Score: 0.004
  47. Manschreck TC. The assessment of paranoid features. Compr Psychiatry. 1979 Jul-Aug; 20(4):370-7.
    View in: PubMed
    Score: 0.004
  48. Manschreck TC, Maher BA, Rucklos ME, White MT. The predictability of thought disordered speech in schizophrenic patients. Br J Psychiatry. 1979 Jun; 134:595-601.
    View in: PubMed
    Score: 0.004
  49. Maher BA, Manschreck TC, Yurgelun-Todd DA, Tsuang MT. Hemispheric asymmetry of frontal and temporal gray matter and age of onset in schizophrenia. Biol Psychiatry. 1998 Sep 15; 44(6):413-7.
    View in: PubMed
    Score: 0.004
  50. Jacobson AM, Silverberg E, Hackett T, Manschreck T. Treatment of Raynaud's disease: evaluation of a behavioral approach. Psychiatr Clin (Basel). 1978; 11(3):125-31.
    View in: PubMed
    Score: 0.004
  51. Blyler CR, Maher BA, Manschreck TC, Fenton WS. Line drawing as a possible measure of lateralized motor performance in schizophrenia. Schizophr Res. 1997 Jul 25; 26(1):15-23.
    View in: PubMed
    Score: 0.004
  52. Maher BA, Manschreck TC, Redmond D, Beaudette S. Length of illness and the gradient from positive to negative semantic priming in schizophrenic patients. Schizophr Res. 1996 Nov 15; 22(2):127-32.
    View in: PubMed
    Score: 0.003
  53. Maher BA, Manschreck TC, Woods BT, Yurgelun-Todd DA, Tsuang MT. Frontal brain volume and context effects in short-term recall in schizophrenia. Biol Psychiatry. 1995 Feb 01; 37(3):144-50.
    View in: PubMed
    Score: 0.003
  54. Jacobson G, Baldessarini RJ, Manschreck T. Tardive and withdrawal dyskinesia associated with haloperidol. Am J Psychiatry. 1974 Aug; 131(8):910-3.
    View in: PubMed
    Score: 0.003
  55. Welch J, Manschreck T, Redmond D. Clozapine-induced seizures and EEG changes. J Neuropsychiatry Clin Neurosci. 1994; 6(3):250-6.
    View in: PubMed
    Score: 0.003
  56. Wilson SN, Surman OS, Colvin R, Ozonoff D, Gelenberg AJ, Jenike MA, Manschreck T, Pato C. Unusual lymphocyte subset distribution in some depressed patients. J Clin Psychiatry. 1990 Feb; 51(2):51-2.
    View in: PubMed
    Score: 0.002
  57. Maher BA, Manschreck TC, Weisstein CC, Schneyer ML, Okunieff R. Cloze analysis in schizophrenic speech: scoring method and raters' education. Percept Mot Skills. 1988 Dec; 67(3):911-8.
    View in: PubMed
    Score: 0.002
  58. Zusky PM, Biederman J, Rosenbaum JF, Manschreck TC, Gross CC, Weilberg JB, Gastfriend DR. Adjunct low dose lithium carbonate in treatment-resistant depression: a placebo-controlled study. J Clin Psychopharmacol. 1988 Apr; 8(2):120-4.
    View in: PubMed
    Score: 0.002
  59. Beckett A, Summergrad P, Manschreck T, Vitagliano H, Henderson M, Buttolph ML, Jenike M. Symptomatic HIV infection of the CNS in a patient without clinical evidence of immune deficiency. Am J Psychiatry. 1987 Oct; 144(10):1342-4.
    View in: PubMed
    Score: 0.002
  60. Zusky P, Manschreck TC, Blanchard C, Rosenbaum J, Elliot C, Lou P. Dothiepin hydrochloride: treatment efficacy and safety. J Clin Psychiatry. 1986 Oct; 47(10):504-7.
    View in: PubMed
    Score: 0.002
  61. Uzogara E, Sheehan DV, Manschreck TC, Jones KJ. A combination drug treatment for acute common migraine. Headache. 1986 May; 26(5):231-6.
    View in: PubMed
    Score: 0.002
  62. Maher BA, Manschreck TC, Molino MA. Redundancy, pause distributions and thought disorder in schizophrenia. Lang Speech. 1983 Apr-Jun; 26 ( Pt 2):191-9.
    View in: PubMed
    Score: 0.001
  63. Sheehan DV, Davidson J, Manschreck T, Van Wyck Fleet J. Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. J Clin Psychopharmacol. 1983 Feb; 3(1):28-31.
    View in: PubMed
    Score: 0.001
  64. Latham C, Holzman PS, Manschreck TC, Tole J. Optokinetic nystagmus and pursuit eye movements in schizophrenia. Arch Gen Psychiatry. 1981 Sep; 38(9):997-1003.
    View in: PubMed
    Score: 0.001
  65. Neu C, Manschreck TC, Flocks JM. Renal damage associated with long term use of lithium carbonate. J Clin Psychiatry. 1979 Nov; 40(11):460-3.
    View in: PubMed
    Score: 0.001
  66. Kalotkin M, Manschreck T, O'Brien D. Electromyographic tension levels in stutterers and normal speakers. Percept Mot Skills. 1979 Aug; 49(1):109-10.
    View in: PubMed
    Score: 0.001
  67. Jacobson AM, Manschreck TC, Silverberg E. Behavioral treatment for Raynaud's disease: a comparative study with long-term follow-up. Am J Psychiatry. 1979 Jun; 136(6):844-6.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.